- Home
- KYNB vs NRSN Comparison
KYNB vs NRSN Comparison
Compare KYNB & NRSN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | KYNB | NRSN |
|---|---|---|
| Founded | 1993 | 2017 |
| Country | United States | Israel |
| Employees | 34 | 16 |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 27.6M | 26.5M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | KYNB | NRSN |
|---|---|---|
| Price | $6.90 | $0.81 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $8.50 |
| AVG Volume (30 Days) | 7.0K | ★ 121.3K |
| Earning Date | 05-04-2026 | 03-31-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $583.67 |
| P/E Ratio | $0.15 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $6.32 | $0.63 |
| 52 Week High | $9.58 | $2.60 |
Technical Indicators
Market Signals| Indicator | KYNB | NRSN |
|---|---|---|
| Relative Strength Index (RSI) | 48.36 | 48.55 |
| Support Level | $6.73 | $0.67 |
| Resistance Level | $7.42 | $0.86 |
| Average True Range (ATR) | 0.18 | 0.07 |
| MACD | 0.01 | -0.00 |
| Stochastic Oscillator | 39.55 | 37.71 |
Price Performance
Historical ComparisonAbout KYNB Kyntra Bio Inc. Common Stock
Kyntra Bio Inc is a biopharmaceutical company focused on the development of novel therapies in oncology and rare disease. The company's research programs target cancer and rare disease indications, including anemia associated with lower-risk myelodysplastic syndrome (LR-MDS) and metastatic castration-resistant prostate cancer (mCRPC). Itd pipeline drug candidates include Roxadustat and FG-3246.
About NRSN NeuroSense Therapeutics Ltd.
NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. These diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease, and Parkinson's disease, among others. Its product candidate, PrimeC, is a novel extended-release, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.